Thus, a potential ERBB2-MK2-ZFP36/TTP phosphorylation axis is operative in ERBB2-amplified cancers, which can be targeted by inhibitors of the MAPK-MK2 pathway. The gene discussed is ZFP36; the disease is cancer.